What the Research Says About Creatine and Depression

You've optimized your diet, you're exercising regularly, and you've tried multiple antidepressants. Yet the fog persists. Depression affects over 300 million people worldwide, and for many, standard treatments deliver incomplete relief or come with side effects that make adherence difficult. Now a supplement better known for building muscle is emerging as a potential tool for brain health. The question is whether creatine's promise for depression is backed by solid evidence or premature hype.

Depression often involves disrupted brain energy metabolism, and creatine plays a direct role in cellular energy production. Superpower's baseline panel tests the nutritional and metabolic markers that influence how your brain generates and uses energy, including factors that determine whether supplementation might address an underlying deficit.

Key Takeaways

• Creatine supports brain energy by replenishing ATP, the molecule that powers cellular function.
• Lower brain creatine levels have been observed in individuals with more severe depression.
• Clinical trials show modest reductions in depressive symptoms, particularly when combined with antidepressants.
• The average effect size is small and may not reach clinical significance for most individuals.
• Evidence quality is limited by small sample sizes and potential publication bias.
• Standard doses in trials range from 4 to 5 grams daily of creatine monohydrate.
• Larger, more rigorous studies are needed before creatine can be recommended as standard adjunctive treatment.

How Creatine Functions in Brain Energy Metabolism

Creatine is a naturally occurring compound synthesized in the liver, kidneys, and pancreas from the amino acids glycine, arginine, and methionine. It's also obtained through diet, primarily from meat and fish. Once absorbed, creatine enters cells and is phosphorylated to form phosphocreatine, a high-energy molecule that serves as a rapid reserve for ATP regeneration.

ATP is the universal energy currency of cells. When neurons fire, transmit signals, or maintain ion gradients across membranes, they consume ATP. In high-demand tissues like the brain, ATP depletion can occur quickly. Phosphocreatine acts as a buffer, donating its phosphate group to ADP to regenerate ATP almost instantaneously. This system is especially important in brain regions with high metabolic activity, such as the prefrontal cortex, which is heavily implicated in mood regulation and executive function.

Oral creatine supplementation increases brain creatine and phosphocreatine concentrations, as demonstrated by magnetic resonance spectroscopy studies. These increases suggest that exogenous creatine can cross the blood-brain barrier and enhance the brain's capacity to meet energy demands.

The Brain Energy Deficit Hypothesis of Depression

Depression has traditionally been understood through the lens of neurotransmitter imbalances, particularly serotonin, norepinephrine, and dopamine. While this framework has guided the development of most antidepressants, it doesn't fully explain why many patients don't respond to these medications or why symptoms often persist despite biochemical correction. An emerging hypothesis suggests that depression may also involve a failure of cellular energy metabolism.

Neuroimaging studies using phosphorus magnetic resonance spectroscopy have found reduced levels of phosphocreatine and ATP in the brains of individuals with major depressive disorder, particularly in the prefrontal cortex and anterior cingulate cortex. These regions are critical for emotional regulation, decision-making, and cognitive control. When energy availability is compromised:

• Neuronal function becomes less efficient.
• Synaptic plasticity is impaired.
• The brain's ability to adapt to stress diminishes.

Mitochondrial dysfunction has also been observed in depression. Mitochondria are the organelles responsible for producing the majority of cellular ATP through oxidative phosphorylation. When mitochondrial function is impaired, cells rely more heavily on less efficient anaerobic pathways, and the phosphocreatine system becomes even more important as a compensatory energy buffer. By increasing phosphocreatine availability, creatine supplementation may help stabilize energy supply during periods of high neuronal demand.

Additionally, creatine appears to influence several other pathways relevant to depression:

• It modulates brain-derived neurotrophic factor (BDNF), a protein that supports neuronal survival and plasticity.
• It may affect neurotransmitter systems, including serotonergic and dopaminergic signaling.
• Some preclinical studies suggest creatine has neuroprotective effects against oxidative stress and excitotoxicity (2016 literature review).

Observational links between creatine intake and depression risk

A large cross-sectional study using data from the National Health and Nutrition Examination Survey found an inverse relationship between dietary creatine intake and depression prevalence among U.S. adults. Individuals with higher creatine consumption from food sources had lower odds of depression, even after adjusting for confounding variables such as age, sex, physical activity, and overall diet quality. While this type of study cannot establish causation, it adds to the biological plausibility that creatine status may influence mood.

What Clinical Trials Show About Creatine for Depression

A systematic review and meta-analysis published in the British Journal of Nutrition in 2025 synthesized data from eleven randomized controlled trials involving 1,093 participants. Pooled analyses suggest a modest but potentially meaningful effect size for creatine supplementation on depressive symptoms. For context, a reduction of 3 points on this scale is generally considered the minimal clinically important difference. The confidence interval for the effect included zero, meaning the true effect could be trivial or even absent.

Heterogeneity across studies was substantial, with an I² value of 71.3%, indicating that results varied considerably between trials. Some of this variation may be explained by differences in study populations. Trials conducted in individuals with clinically diagnosed depression appeared to show larger effects than those in non-depressed populations, though subgroup analyses also revealed signs of publication bias favoring positive results.

One of the most cited trials, published in the American Journal of Psychiatry in 2012, enrolled women with major depressive disorder who were already taking a selective serotonin reuptake inhibitor (SSRI) but had not achieved full remission. Participants were randomized to receive either 5 grams of creatine monohydrate daily or placebo for eight weeks. The creatine group showed significantly greater improvement in depressive symptoms compared to placebo, with the effect emerging as early as two weeks.

A dose-ranging study in adolescent females with SSRI-resistant depression used phosphorus magnetic resonance spectroscopy to measure brain phosphocreatine levels before and after supplementation. The study found that higher doses of creatine (10 grams daily) increased brain phosphocreatine more than lower doses (2 or 5 grams), and that these increases correlated with reductions in depressive symptoms (2022 literature review). This suggests a dose-response relationship and provides mechanistic support for the clinical findings, though the sample size was small.

Evidence for remission and response rates

Secondary outcomes from the meta-analysis included remission and treatment response. Remission, defined as achieving a Hamilton Depression Rating Scale score below a specified threshold, was significantly more likely in the creatine groups across three trials, with an odds ratio of 3.60. However, treatment response, typically defined as a 50% reduction in symptom severity, did not differ significantly between creatine and placebo groups in the two trials that reported this outcome. This discrepancy suggests that while creatine may help some individuals achieve full symptom resolution, it may not consistently produce the magnitude of improvement that defines clinical response.

Limitations and sources of bias

The certainty of evidence was rated as very low according to GRADE criteria, meaning the true effect of creatine on depression remains highly uncertain (2025 meta-analysis). Several factors contribute to this rating:

• Most trials were small, with sample sizes ranging from 20 to 60 participants.
• Many studies were conducted at single centers, which tends to produce larger treatment effects than multicenter trials.
• Some trials did not adequately describe randomization procedures or allocation concealment.
• Blinding was not always clearly maintained.
• Selective outcome reporting was a concern, as not all trials registered protocols in advance.
• Funnel plot asymmetry suggested potential publication bias, with smaller studies showing larger effects (2023 meta-analysis).

Dosing, Form, and Timing Considerations

Standard dosing protocols

The most commonly studied dose in depression trials is 5 grams of creatine monohydrate per day, taken orally. Some studies have used loading phases (10 to 20 grams daily for the first week) followed by maintenance doses, while others have used consistent daily dosing without a loading phase. The dose-ranging study in adolescents suggested that 10 grams daily may produce greater increases in brain phosphocreatine than 5 grams, though whether this translates to superior clinical outcomes is not yet established. Creatine monohydrate is the form used in nearly all clinical trials. It is inexpensive, well-studied, and has high bioavailability.

Timing and co-administration

Creatine does not need to be taken at a specific time of day, as its effects depend on tissue saturation rather than acute dosing. Consistent daily intake is more important than timing. Some evidence suggests that taking creatine with carbohydrates may enhance muscle uptake via insulin-mediated transport, though whether this applies to brain uptake is unclear (2022 literature review). Creatine has been studied almost exclusively as an adjunct to antidepressant medication rather than as monotherapy. The rationale is that creatine may address a complementary mechanism (energy metabolism) while SSRIs or SNRIs target monoaminergic neurotransmission.

Duration of supplementation

Brain creatine levels increase gradually with supplementation, typically reaching a plateau after several weeks. Most trials lasted eight to twelve weeks, which is long enough to observe changes in depressive symptoms if creatine is effective. Some studies reported early effects within two weeks, but sustained benefit over longer periods has not been rigorously evaluated. It is not known whether creatine needs to be continued indefinitely to maintain benefit or whether effects persist after discontinuation.

Who May Benefit Most, and Who Should Exercise Caution

The strongest evidence for creatine in depression comes from studies in women with major depressive disorder who were already taking an SSRI but had not achieved full remission. This suggests that creatine may be most useful as an augmentation strategy in individuals with partial treatment response rather than as a first-line intervention. Whether men respond similarly is unclear, as most trials enrolled predominantly or exclusively female participants.

Individuals with lower baseline brain creatine levels, as measured by magnetic resonance spectroscopy, may be more likely to benefit from supplementation. However, brain creatine measurement is not clinically accessible outside of research settings. Dietary creatine intake is another potential marker; individuals who consume little or no meat or fish (such as vegetarians and vegans) have lower endogenous creatine stores and may experience greater increases in brain creatine with supplementation. Adolescents and young adults with treatment-resistant depression have been studied in small trials, with some evidence of benefit.

Creatine monohydrate is generally well tolerated at doses up to 10 grams daily. The most commonly reported side effects are mild gastrointestinal discomfort and weight gain due to water retention in muscle tissue. These effects are typically transient and do not lead to discontinuation. Concerns about kidney function have been raised, as creatine is metabolized to creatinine, a waste product excreted by the kidneys. However, extensive research in healthy individuals and athletes has not found evidence that creatine supplementation impairs kidney function. Individuals with pre-existing kidney disease should consult a physician before using creatine.

Creatine does not appear to interact with SSRIs, SNRIs, or other common antidepressants. One small trial combined creatine with 5-hydroxytryptophan, a serotonin precursor, without adverse effects, though this combination has not been studied in larger samples. There is no evidence that creatine worsens mania or increases suicide risk, but individuals with bipolar disorder should be monitored closely when starting any new treatment.

Measuring Response: Biomarkers and Functional Outcomes

Unlike some supplements where subjective symptom improvement is the only available endpoint, creatine's effects on brain metabolism can be measured directly using phosphorus magnetic resonance spectroscopy. This technique quantifies phosphocreatine and ATP levels in specific brain regions, providing an objective marker of target engagement. Studies that have used this approach have found that increases in brain phosphocreatine correlate with reductions in depressive symptoms, supporting the hypothesis that energy metabolism is a relevant therapeutic target.

However, magnetic resonance spectroscopy is not widely available and is not practical for routine clinical use. In the absence of direct brain imaging, clinicians and patients must rely on symptom scales such as the Hamilton Depression Rating Scale or the Beck Depression Inventory to assess response. These scales capture changes in mood, sleep, appetite, energy, and cognitive function, but they are subjective and can be influenced by placebo effects, expectation, and reporting bias.

Functional outcomes, such as return to work, social engagement, and quality of life, are arguably more meaningful than symptom scale scores, but few creatine trials have reported these endpoints. Future research should prioritize patient-centered outcomes that reflect real-world functioning rather than focusing exclusively on symptom severity. Baseline metabolic markers may also be relevant. Fasting glucose, insulin, and markers of mitochondrial function could theoretically predict who is most likely to benefit from creatine, though this has not been tested. Inflammatory markers such as high-sensitivity C-reactive protein may also be relevant, as inflammation is increasingly recognized as a contributor to depression and may interact with energy metabolism.

Testing Your Metabolic and Nutritional Foundation

Depression is rarely caused by a single factor, and effective treatment often requires addressing multiple underlying contributors. Energy metabolism, inflammation, nutrient deficiencies, and hormonal imbalances can all influence mood and cognitive function. Superpower's 100+ biomarker panel provides a comprehensive view of these systems, including markers that are directly relevant to the mechanisms by which creatine may exert its effects.

Testing fasting glucose, hemoglobin A1c, and insulin reveals how efficiently your body manages energy at the cellular level. Measuring vitamin D, vitamin B12, and ferritin identifies nutritional deficits that can mimic or worsen depressive symptoms. Inflammatory markers and thyroid function provide additional context for understanding why standard treatments may not be working. Rather than guessing whether creatine or any other intervention is appropriate, testing gives you an objective starting point and a way to track whether changes in your biology correspond to changes in how you feel.